Skip to content

EOD v2.1 Changes

Jump to bottom
Aaron Hall edited this page Aug 3, 2021 · 1 revision

EOD v2.1 changes

EOD and SS2018 - includes changes to schema definitions, EOD fields and SS2018

  • Formal Schema Name: The formal name for the Cervix and Corpus schemas were revised to include Uteri:

    • Cervix Uteri [8th: 2018-2020]
    • Cervix Uteri [9th: 2021+]
    • Corpus Uteri Adenosarcoma
    • Corpus Uteri Carcinoma and Carcinosarcoma
    • Corpus Uteri Sarcoma

  • General Change EOD fields:

    • EOD Primary Tumor, EOD Regional Nodes, EOD Mets, EOD Prostate Pathological Extension: for the unknown code, the phrase 'not documented in patient record' was changed to be 'not documented in medical record'
    • EOD Regional Nodes: Note was added (the # differs by schema) specifying to code 800 if regional lymph nodes are involved but which node isn't specified. This was not added to
      • Colon and Rectum (already had note)
      • Kaposi Sarcoma, Mycosis Fungoides
      • Brain, CNS Other, Intracranial Gland, Lymphoma, Lymphoma CLL/SLL, HemeRetic (Lymph nodes not applicable)
      • Soft Tissue Rare, Soft Tissue Other, Soft Tissue Abdomen and Thoracic (800 is only positive node code)

  • Histology:

    • 8444, 8473 and 8965 were removed in v2.0 and should not have been. They were re-added.
    • 8455, 8483, 8484, 8859, 8976, 9111, 9366-9368 were added for 2022.
    • 9700-9701 were moved from all other schemas into Mycosis Fungoides (Schema ID = 00811). The only exceptions are Brain, CNS Other and Intracranial Gland for /0 and /1. See EOD v2.1 Review and Conversion.

  • TNM Edition Number [1060]: If the AJCC ID is defined (is not XX), even if none of T, N, M or Stage Group are defined, the TNM Edition Number is now being set to 08. This affects Brain, CNS Other, HemeRetic, Intracranial Gland, Kaposi Sarcoma, Plasma Cell Disorders, Plasma Cell Myeloma, and Soft Tissue Rare schemas.

  • Appendix, Anus

  • Appendix

    • EOD Primary Tumor; Code 000 was modified to include High-grade appendiceal mucinous neoplasm (HAMN)
    • SS2018: Code 0 modified to include Low-grade appendical mucinous neoplasm (LAMN) and High-grade appendiceal mucinous neoplasm (HAMN)

  • Bladder

    • EOD Primary Tumor: Note 3 had bullet added describing when to use Code 050, existing bullet for Code 000 revised

  • Bladder, Kidney Renal Pelvis, Urethra, Urethra-Prostatic

    • SS2018: Code 0 has 'In situ, intraepithelial, noninvasive' replaced as the first line

  • Bone Appendicular Skeleton, Bone Pelvis, Bone Spine

    • SS2018: Spinal Canal was moved from Code 7 to Code 2 for Spine (C412)

  • Brain, CNS Other, Intracranial Gland Schema and AJCC ID: Schema selection and AJCC ID calculation were restructured to show 8000-9993 for Beh=0, 1 to simplify the logic

  • Breast

    • AJCC ID: 8509/2 is now considered AJCC eligible and will have an AJCC ID of 48.1 (Breast DCIS). See EOD v2.1 Review and Conversion.
    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Buccal Mucosa, Floor of Mouth

    • EOD Primary Tumor: Note 4 modified to specify Invasion, rather than involvement, of cortical bone; Code 600 changed to be "Invasion through cortical bone"

  • Buccal Mucosa

    • SS2018: Note 4 about cortical bone modified to specify Invasion rather than involvement and to assign Code 7

  • Buccal Mucosa, Floor of Mouth, Gum, Lip, Mouth Other, Palate Hard, Tongue Anterior

    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Cervical Lymph Nodes and Unknown Primary (of Head and Neck), Ill-Defined Other

    • Schema: Cervical Lymph Nodes and Unknown Primary was revised to only include those histologies that are eligible for AJCC staging. The other histologies were moved to Ill-Defined Sites. See EOD v2.1 Review and Conversion.

  • Cervical Lymph Nodes and Unknown Primary (of Head and Neck)

    • EOD Regional Nodes: Note 3 Clinical assessment had an exception added related to neoadjuvant therapy

  • Cervix [8th]

    • EOD Primary Tumor: Code 550 text was corrected (copy/paste error introduced in v2.0)

  • Cervix [V9]

    • AJCC ID: Histologies 8045, 8054, 8085-8086, 8154, 8246, 8430, 8483-8484 will now return AJCC ID of 52; Histologies 8200, 8720 will now return AJCC ID of XX. See EOD v2.1 Review and Conversion.

  • Cervix [8th], Cervix [V9], Vagina, Vulva

    • EOD Regional Nodes: Lymph nodes have been restructured, but no change to codes or meaning
    • SS2018: Codes 3 and 7 had the lymph nodes restructured, but no changes to codes.

  • Cervix Sarcoma – New schema

    • Schema: Cervix Sarcoma was added as Schema ID = 00528 and the histologies were removed from other schemas including Cervix, GIST, Soft Tissue Abdomen and Thoracic, Soft Tissue Rare, and Soft Tissue Other. See EOD v2.1 Review and Conversion.

  • Colon and Rectum

    • AJCC ID: 8033, 8262 are now considered AJCC eligible and will have an AJCC ID of 20. See EOD v2.1 Review and Conversion.
    • EOD Regional Nodes: Note 3 added specifying when to use Code 200; 'PATHOLOGICIAL assessment only' was added to Code 200

  • Corpus Carcinoma and Carcinosarcoma

    • AJCC ID: 8441/2 is now considered AJCC eligible and will have an AJCC ID of 53. See EOD v2.1 Review and Conversion.
    • EOD Primary Tumor: Codes 070 and 080 were removed; Code 000 was updated for EIN; Code 050 was updated for SEIC; Note 2 modified to only refer to Code 050. See EOD v2.1 Review and Conversion.
    • EOD Regional Nodes: Code 600 was updated to include 'Size of lymph node metastasis unknown'
    • SS2018: Code 0 modified to include SEIC

  • Cutaneous Squamous Cell Carcinoma of the Head and Neck

    • AJCC ID: 8400 is no longer AJCC eligible, while 8402 is now an AJCC eligible histology. See EOD v2.1 Review and Conversion.
    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Fallopian Tube, Ovary

    • EOD Primary Tumor: Note 2 was restructured; Code 000 modified to include Low Grade and No grade STIC

  • Gallbladder

    • EOD Regional Nodes: Code 300 had Portacaval added
    • SS2018: Code 3 had Portacaval added

  • Gum, Lip, Mouth Other, Palate Hard, Tongue Anterior

    • EOD Primary Tumor: Note 4 modified to specify Invasion, rather than involvement, of cortical bone;

  • Heart, Mediastinum and Pleura, Retroperitoneum, Soft Tissue Abdomen and Thoracic, Soft Tissue Head and Neck, Soft Tissue Trunk and Extremities, Soft Tissue Rare

  • HemeRetic

    • Regional Nodes Positive, Regional Nodes Examined: These had been limited to 99, but are now using the standard validate tables for these fields

  • Hypopharynx

    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Kaposi Sarcoma

    • EOD Primary Tumor: Note 2: had bullets added describing when to use Codes 100, 200 and 300

  • Larynx Glottic, Larynx Other, Larynx Subglottic, Larynx Supraglottic

    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Liver

    • EOD Primary Tumor: Note 3 was added describing the lobes of the liver

  • Lymphoma

  • Lymphoma, Lymphoma CLL/SLL

    • EOD Primary Tumor: Code 700 modified to include multiple extra-lymphatic organs/sites
    • SS2018: Code 7 modified to include multiple extra-lymphatic organs/sites

  • Major Salivary Glands, Maxillary Sinus, Nasal Cavity and Ethmoid Sinus

    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Merkel Cell

    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Mouth Other

    • SS2018: Note 4 about cortical bone modified to specify Invasion rather than involvement and to assign Code 7

  • Oropharynx HPV-Mediated (p16+), Oropharynx (p16-)

    • EOD Primary Tumor: Base of Tongue for Lingual Tonsil moved from Code 200 to Code 100
    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy
    • SS2018: Base of Tongue for Lingual Tonsil moved from Code 2 to Code 1

  • Ovary, Primary Peritoneal Carcinoma

    • SS2018: Code 0 restructured, changed to ovarian mucosa, and STIC was added; Code 2, Adjacent (pelvic) peritoneum), remove extra parenthesis

  • Orbital Sarcoma

    • Schema: Additional review by AJCC cause the following adjustment related to Soft Tissue Other/Soft Tissue Rare
      • C690-C695, C699, C723 with 9222 were moved to Soft Tissue Rare (Schema ID = 00450, AJCC ID = 45)
      • C696, C698 with 9222 were moved to Soft Tissue Other (Schema ID = 00459, AJCC ID = XX)

  • Penis

    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy

  • Pleural Mesothelioma

  • Prostate

    • EOD Primary Tumor: Note 2 added to code field based on DRE
    • EOD Prostate Path Extension: Note 1 had bullet added to code TURP and simple prostatectomies in EOD Primary Tumor and the phrase about simple prostatectomy with negative margins was removed; Note 7 about when to use Code 950 was added

  • Skin Other

    • EOD Primary Tumor: Code 200 was revised to include Bone and Cartilage

  • Small Intestine

  • Soft Tissue Abdomen and Thoracic, Soft Tissue Trunk and Extremities

    • Schema: C474 was moved from Soft Tissue Abdomen and Thoracic into Soft Tissue Trunk and Extremities for diagnosis years 2018-2020. (This change was made for diagnosis years 2021 and later in version 2.0). See EOD v2.1 Review and Conversion.

  • Soft Tissue Other and Soft Tissue Rare

    • Schema: Soft Tissue Other was split into Soft Tissue Rare with Schema ID = 00450 which includes all combinations where AJCC ID = 45 and Soft Tissue Other with Schema ID = 00459 which includes all combinations where AJCC ID = XX. See EOD v2.1 Review and Conversion.
    • Schema: Additional review by AJCC caused the following additional adjustments where the listed combinations are moving to Soft Tissue Other (00459) and AJCC ID = XX:
      • C473, C475, C493-C495 with 8901, 8910-8920, 9120, 9133, 9180 and Schema Discriminator 2 = 9
      • C481-C488 with 8806, 8930-8931 and Sex = 4
      • C696, C698 with 8930-8931, 8991, 9020, 9180, 9231
    • Schema: Additional review by AJCC cause the following adjustment related to Orbital Sarcoma (00700)
      • C690-C695, C699, C723 with 9222 are included in Soft Tissue Rare (Schema ID = 00450, AJCC ID = 45)
      • C696, C698 with 9222 are included in Soft Tissue Other (Schema ID = 00459, AJCC ID = XX)

  • Stomach

    • AJCC ID: 8213 is now considered AJCC eligible and will have an AJCC ID of 17. See EOD v2.1 Review and Conversion.
    • Schema Notes: Note 3 discussing EGJ was modified

  • Testis

    • EOD Primary Tumor: Code 300 is now contributing an L to Summary Stage instead of RE
    • EOD Regional Nodes: Note 2 Clinical assessment had an exception added related to neoadjuvant therapy
    • SS2018: Code 1 modified to be with or without LVI, confined to testis, NOS also added; Code 2 had with LVI and limited to testis removed.

  • Thyroid, Thyroid Medullary

    • EOD Regional Nodes: Code 000 revised to specify Microscopic assessment only; Code 050 revised to specify Clinical assessment only

  • Vagina

    • EOD Regional Nodes: Note 4 was added related to code 800; Code 300 was restructured and para-aortic nodes were moved to the new Code 400
    • EOD Mets: Code 10 was restructured and para-aortic was moved from the all sites category into the lower third category

SSDI and Grade - NAACCR is the custodian of these fields, changes are listed here for convenience. See Change Log on https://apps.naaccr.org/ssdi/list/ for complete information.

  • Metadata changes: These are changes to information available about the SSDIs

    • Year Ranges: there is now a start and end year associated with SSDI and with each standard setter who requires the SSDI. If Start is blank, the default is 2018. If End is blank, the default is through the present. If the SSDI was implemented after 2018, the SSDI start will have a value.
    • SEER (RC): a new tag has been added to track specifically when an SSDI is required by SEER if the incident cancer was collected as an analytic case from a CoC Facility (CoC Accredited Flag [2152] = 1) This is noted in NAACCR Volume II, Chapter VIII as RC. The underlying tag is 'SEER_REQUIRED_WHEN_COC_ANALYTIC'

  • General

    • Grade Pathological [3844]: Note about when clinical workup should be used revised – last bullet under Surgical Resection was moved to its own category of No Surgical Resection
    • Grade Post Therapy Clin (yc) [1068]: Note 1 regarding when to leave field blank had bullet added for when neoadjuvant therapy completed but no microscopic exam was done; Not required for CCCR
    • Grade Post Therapy Path (yp) [3845]: Note 1 regarding when to leave field blank had bullet added for when neoadjuvant therapy completed but no surgery was performed; Note 2 regarding how to code when preferred grading system not available for yPath was added to those schemas with a preferred grading system; Note added (number varies) detailing when the grade from clinical work up can be used
    • SSDIs effective AFTER 2018: Note 1 was added to all new SSDIs indicating the start year. A 'blank' code was added to the possible code list for years prior to the effect start date. P16
    • SSDIs no longer required by any standard setters: Note 1 was added to SSDIs indicating the year after which no standard setter is collecting the code. A 'blank' code was added to the possible code list for years after the last required year.
    • Unknown code (XX9, 99, etc): the phrase 'not documented in patient record' was changed to be 'not documented in medical record'

  • Bile Duct Intrahepatic

    • Tumor Growth Patterns [3935]: not required by SEER after 2021

  • Bile Duct Intrahepatic, Bile Duct Perihilar

    • Primary Scleros Cholangitis [3917]: not required by SEER after 2021

  • Bladder, Kidney Renal Pelvis, Urethra, Urethra-Prostatic

    • Grade Post Therapy Pathological [3845]: Note 7 specifying that TURB does not qualify for Surgical resection of bladder was added

  • Brain, CNS Other, Intracranial Gland

    • Brain Molecular Markers [3816]: Note 1 modified to clarify priority of 85 and 99 if both seem to apply
    • Grade Clinical [3843]: Note 2 added to indicate that Grade Clinical can be assigned without histologic confirmation if histology is based on imaging

  • Breast

    • ER Summary [3827], PR Summary [3915], HER2 Summary [3855]: Note 3 revised to specify evidence of in situ or invasive carcinoma; Note 4 revised to specify the invasive and in situ components described are in the primary tumor
    • ER Percent Positive [3826], PR Percent Positive [3914]: Note 6 added describing how to code ranges other than the ones given in the codes
    • HER2 IHC Summary [3850], HER2 ISH Summary [3854]: These are no longer required by CCCR, CoC or SEER (No standard setters are requiring these)
    • HER2 ISH DP Copy Ratio [3852], HER2 ISH DP Copy No [3851], HER2 ISH SP Copy No [3853]: These are no longer required by CoC or SEER (No standard setters are requiring these)
    • Lymph Nodes Positive Axillary Level I-II [3882]: Note 4 was revised, 'removed' changed to 'positive' and examples were added
    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical [1068], Grade Post Therapy Pathological [3845]: Codes 1-3 modified to include Nottingham/Scarff Bloom-Richardson grade
    • Grade Post Therapy Pathological [3845]: Note 5 related to priority order was added; Note 8 describing when nodal tissue can be used was added

  • Cervix V9

    • p16[3956]: added for 2021 and later

  • Cervix 8th, Cervix V9, Vagina, Vulva

    • LN Status Femoral-Inguinal, Para-Aortic, Pelvic [3884]: Retired (It will be removed from all schemas next year); it is replaced by the related SSDIs. Note 1 added stating this field should no longer be coded and indicating the replacement fields; blank added to code list for cases collected after new fields are available
    • LN Status: Femoral-Inguinal [3959]: added to Vagina and Vulva
    • LN Status: Para-aortic [3958]: added to Cervix 8th, Cervix V9 and Vagina
    • LN Status: Pelvic [3957]: added to Cervix 8th, Cervix V9, Vagina, and Vulva. See EOD v2.1 Review and Conversion.
    • LN Assessment: Femoral-Inguinal [3871]: Note 2 added to list applicable lymph nodes; Note 4 added to not include ITCs; Notes updated to indicate LN Status, Femoral-Inguinal; Code 2 had 'Sentinel node biopsy' added; Codes 7 and 9 had Regional replaced with 'Femoral-inguinal'; Removed from Cervix 8th and Cervix V9.
    • LN Assessment: Para-Aortic [3872]: Note 2 added to list applicable lymph nodes; Note 4 added to not include ITCs; Notes updated to indicate LN Status: Para-Aortic; Code 2 had 'Sentinel node biopsy' added; Codes 7 and 9 had Regional replaced with 'Para-Aortic'; Removed from Vulva.
    • LN Assessment: Pelvic [3873]: Note 2 added for Vulva that pelvic nodes are distant; Note added to list applicable lymph nodes; Note added to not include ITCs; Notes updated to indicate LN Status: Pelvic; Code 2 had 'Sentinel node biopsy' added; Codes 7 and 9 had Regional replaced with 'Pelvic'

  • Colon and Rectum

    • BRAF Mutational Analysis [3940], NRAS Mutational Analysis [3941]: these are now required by CoC
    • Microsatellite Instability [3890]: Note 3 added indicating results from nodal and metastatic tissue may be used; Code 9 updated to include MSI-equivocal

  • Corpus Adenosarcoma, Corpus Carcinoma and Carcinosarcoma, Corpus Sarcoma, Cervix Sarcoma

    • Number of Examined Para-aortic Nodes [3899], Number of Examined Pelvic Nodes [3900]: Note 2 added to list applicable lymph nodes; Note 3 excluding ITCs was removed; Note 4 describing when to code X9 was modified to clarify dissection and when 00, X6 and X9 should be used
    • Number of Positive Para-aortic Nodes [3901], Number of Positive Pelvic Nodes [3902]: Note 2 added to list applicable lymph nodes; Note 5 describing when to code X9 was modified to clarify dissection and when X6 should be used

  • Corpus Carcinoma and Carcinosarcoma

    • FIGO Stage [3936]: Note 5 was added to describe how to code EIC and SEIC

  • Esophagus, Esophagus Squamous, Stomach

    • HER2 Overall Summary [3855]: added Code 8 for not applicable/not collected

  • Fallopian Tube, Ovary

    • CA-125 PreTX Interpretation [3818]: CA-125 changed to CA-125 II in all notes, this is the next generation test
    • FIGO Stage [3936]: Note 5 was added to describe how to code High-grade STIC and LGSC

  • Fallopian Tube, Ovary, Primary Peritoneal Carcinoma

    • Residual Tumor Volume Post Cytoreduction [3921]: Note 2 added describing where the information can be found

  • GIST

    • KIT Gene Immunohistochemistry [3865]: Note 4 added indicating results from nodal and metastatic tissue may be used

  • Heart Mediastinum and Pleura, Kaposi Sarcoma, Orbital Sarcoma, Retroperitoneum, Soft Tissue Abdomen and Thoracic, Soft Tissue Head and Neck, Soft Tissue Other, Soft Tissue Rare, Soft Tissue Trunk and Extremities

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical [1068], Grade Post Therapy Pathological [3845]: Codes 1-3 modified to include FNCLCC Grade

  • Ill-Defined Other

    • Grade Post Therapy Clinical [1068], Grade Post Therapy Pathological [3845]: fixed typos in notes referred to the incorrect field or using the old field name

  • Kidney Parenchyma

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical [1068], Grade Post Therapy Pathological [3845]: Note about Fuhrman grade was removed; Codes 1-4 modified to include WHO/ISUP Grade value; Code 9 modified to include only Fuhrman grade documented
    • Sarcomatoid Features [3925]: Note 5 and Code XX5 were added to handle when sarcomatoid features are only present from a metastatic site

  • Lung

    • ALK Rearrangement [3938], EGFR Mutational Analysis [3939]: these are now required by CoC

  • Lymphoma, Lymphoma CLL/SLL

    • HIV Status [3859]: This is no longer required by CoC; Note 5 was added indicating how to code a history of HIV

  • Lymphoma CLL/SLL

    • Derived Rai Stage [3955]: added for 2018 and later as an output, value will be derived based on Lymphocytosis [3885], Adenopathy [3804], Organomegaly [3907], Anemia [3811] and Thrombocytopenia [3933]
    • Lymphocytosis [3885], Adenopathy [3804], Organomegaly [3907], Anemia [3811] and Thrombocytopenia [3933]: Note 2 added specifying Code 5 should be used if primary site is not C421; Code 5 was added
    • Lymphocytosis [3885]: Old Note 4 indicating lab value takes precedence was removed; Note 5 was revised to indicate that physician statement of Rai stage should take priority when conflicting information exists and it was moved to the end; Code 6 was modified to include a physician statement of Rai stage; Code 9 was modified to clarify that no Rai stage or lymphocytosis were documented
    • Adenopathy [3804], Organomegaly [3907]: Note 7 was added indicating that physician statement of Rai stage should take priority when conflicting information exists; Codes 0 and 1 were revised to indicate the corresponding Rai stage; Code 9 was revised to modified to clarify that no Rai stage or the SSDI were document OR Rai stage was II/III-IV without documentation of the SSDI
    • Anemia [3811] and Thrombocytopenia [3933]: ; Note 4 was revised to indicate that physician statement of Rai stage should take priority when conflicting information exists and it was moved to the end; Codes 0 and 6 were revised to indicate the corresponding Rai stage; Code 9 was revised to modified to clarify that no Rai state or the SSDI were document OR (for Anemia) Rai stage was IV without documentation of the SSDI

  • Lymphoma Ocular Adnexa

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical [1068], Grade Post Therapy Pathological [3845]: Code 1 and 2 modified to specify 10 HPF

  • NET Ampulla of Vater, NET Appendix, NET Colon and Rectum, NET Duodenum, NET Jejunum and Ileum, NET Pancreas, NET Stomach

    • Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clinical [1068], Grade Post Therapy Pathological [3845]: 'or 2mm2' added to the mitotic count descriptor; Stated as WHO Grade added to grades 1 through 3

  • Melanoma Skin

    • Ulceration [3836]: bullet added to Note 2 indicating ulcerated lesions on PE and ulceration on microscopic exam differ; bullets added to Note 3 describing when to use Codes 0 and 1 and that ulceration must be caused by the melanoma

  • Pancreas

    • CA 19-9 PreTX Lab Value [3942]: this is now required by CoC; Note 4 about known lab values was added; Codes XXXX.2 and XXXX.3 for lab value not available were added

  • Plasma Cell Myeloma

    • LDH (Lactate Dehydrogenase) Level [3869]: 'Pretreatment' removed from the name and 'pretx_' removed from the data item tag; this change was carried through the notes for this data item
    • High Risk Cytogenetics [3857], LDH Level [3869], Serum Albumin Pretreatment Level [3930], Serum Beta-2 Microglobulin Pretreatment Level [3931]: Note 4 changed to indicate Code 5 should be used that if Schema Discriminator 1 = 1 or 9; Code 5 was added. See EOD v2.1 Review and Conversion.

  • Pleura Mesothelioma

    • Pleural Effusion: [3913]: Notes were reorganized and information about when to use Codes 2 and 3 was added; Code 2 had text for physician statement added.

  • Prostate

    • PSA Lab Value [3920]: Note 4 about known lab values was added; Codes XXX.2 and XXX.3 for lab value not available were added
    • Gleason Patterns Clinical [3838], Gleason Score Clinical [3840]: Note 2 was revised to include TRUS and simple prostatectomy as valid procedures; Note 5 was added to Patterns to describe how to code when only the Score is available; Note 7 (old note 6) was revised to include TRUS and simple prostatectomy; these were required by NPCR since 2021
    • Gleason Patterns Pathological [3889]: Note 2 had a bullet added indicating TURP and simple prostatectomy are coded in the Clinical field; Note 4 and 5 were added describing how to code when only the score is known and when different patterns are documented; Code X7 and X9 had 'radical' added before prostatectomy; these were required by NPCR since 2021
    • Gleason Score Pathological [3841]: Note 2 was modified to specify radical prostatectomy and to indicate that TURP and simple prostatectomy results are coded in clinical; Code X7 and X9 were revised to specify radical prostatectomy; these were required by NPCR since 2021
    • Gleason Tertiary Pattern [3842]: Note 3 was modified to specify radical prostatectomy; Code X7 was revised to specify radical prostatectomy
    • Grade Clinical [3843], Grade Post Therapy Clinical [1068]: Note 5 modified to specify that simple prostatectomy are clinical
    • Grade Pathological [3844], Grade Post Therapy Pathological [3845]: Note 6 modified to specify that simple prostatectomy are clinical and radical prostatectomy are pathological

Home

Supported Algorithms

Getting Started

API Documentation

Technical Specifications

Clone this wiki locally